1 Division of Maternal-Fetal Medicine, Beth Israel Deaconess Medical Center , Boston, Massachusetts.
5 Harvard Medical School , Boston, Massachusetts.
Diabetes Technol Ther. 2018 Jun;20(6):413-419. doi: 10.1089/dia.2017.0443. Epub 2018 Jun 14.
To examine trimester-specific associations among glycemic variability, fetal growth, and birthweight in pregnancies with type 1 diabetes mellitus (Type 1 DM).
In this retrospective cohort study of 41 pregnant women with Type 1 DM, we used continuous glucose monitoring (CGM) data to calculate glycemic variability (coefficient of variation of glucose) over a 7-day interval in each trimester. Clinical data, including fetal biometry, birthweight, and perinatal complications, were extracted from medical records.
Women maintained good glycemic control during pregnancy, with mean HbA1c in the first, second, and third trimester 6.5%, 6.1%, and 6.4%, respectively. Sixty-three percent of infants were large for gestational age (LGA). Estimated fetal weight percentile (EFW%ile) and abdominal circumference percentile (AC%ile) increased during pregnancy, consistent with accelerated prenatal growth. Correlations between trimester-specific glycemic variability and EFW, AC, and birthweight were not statistically significant. After maternal age adjustment, glycemic variability was not associated with birthweight for any trimester (adj. β for first trimester: -38.46, 95% CI: -98.58 to 21.66; adj. β for second trimester: -12.20, 95% CI: -51.47 to 27.06; adj. β for third trimester: -26.26, 95% CI: -79.52 to 27.00).
The occurrence of LGA remains very high in contemporary U.S. women with Type 1 DM, despite the use of CGM and overall good glycemic control. Neither HbA1c nor glycemic variability predicted fetal overgrowth or birthweight. Since LGA is a key driver of maternal and newborn complications in pregnancies with Type 1 DM, our data emphasize the importance of investigating both glucose-dependent and glucose-independent underlying mechanisms.
研究 1 型糖尿病(Type 1 DM)孕妇中血糖变异性、胎儿生长和出生体重之间与孕期相关的特定关联。
在这项回顾性队列研究中,我们纳入了 41 名患有 1 型糖尿病的孕妇,使用连续血糖监测(CGM)数据计算了每个孕期 7 天间隔内的血糖变异性(血糖变异系数)。从病历中提取了临床数据,包括胎儿生物测量、出生体重和围产期并发症。
孕妇在孕期保持了良好的血糖控制,孕早期、孕中期和孕晚期的平均 HbA1c 分别为 6.5%、6.1%和 6.4%。63%的婴儿为巨大儿(LGA)。估计胎儿体重百分位数(EFW%ile)和腹围百分位数(AC%ile)在孕期增加,与产前生长加速一致。孕期特定的血糖变异性与 EFW、AC 和出生体重之间没有统计学显著相关性。在校正母亲年龄后,任何孕期的血糖变异性与出生体重均无关(孕早期校正β:-38.46,95%CI:-98.58 至 21.66;孕中期校正β:-12.20,95%CI:-51.47 至 27.06;孕晚期校正β:-26.26,95%CI:-79.52 至 27.00)。
尽管使用 CGM 和总体良好的血糖控制,当代美国 1 型糖尿病女性的巨大儿发生率仍非常高。HbA1c 和血糖变异性均不能预测胎儿过度生长或出生体重。由于 LGA 是 1 型糖尿病妊娠中母婴并发症的关键驱动因素,我们的数据强调了研究血糖依赖和非血糖依赖的潜在机制的重要性。